A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
NCT03559699
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Pyruvate Kinase Deficiency
Anemia, Hemolytic
Interventions
DRUG:
AG-348
Sponsor
Agios Pharmaceuticals, Inc.